DRRX vs. QLI, ITRM, EYEN, SLGL, LPCN, FBRX, VAXX, ACST, UBX, and SNSE
Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Qilian International Holding Group (QLI), Iterum Therapeutics (ITRM), Eyenovia (EYEN), Sol-Gel Technologies (SLGL), Lipocine (LPCN), Forte Biosciences (FBRX), Vaxxinity (VAXX), Acasti Pharma (ACST), Unity Biotechnology (UBX), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical preparations" industry.
DURECT (NASDAQ:DRRX) and Qilian International Holding Group (NASDAQ:QLI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
In the previous week, Qilian International Holding Group had 1 more articles in the media than DURECT. MarketBeat recorded 2 mentions for Qilian International Holding Group and 1 mentions for DURECT. DURECT's average media sentiment score of 0.00 equaled Qilian International Holding Group'saverage media sentiment score.
28.0% of DURECT shares are owned by institutional investors. 4.3% of DURECT shares are owned by insiders. Comparatively, 58.7% of Qilian International Holding Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Qilian International Holding Group has higher revenue and earnings than DURECT.
DURECT has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
DURECT received 315 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. However, 100.00% of users gave Qilian International Holding Group an outperform vote while only 65.83% of users gave DURECT an outperform vote.
DURECT presently has a consensus price target of $27.50, suggesting a potential upside of 2,902.51%. Given DURECT's higher probable upside, equities analysts clearly believe DURECT is more favorable than Qilian International Holding Group.
Qilian International Holding Group has a net margin of 0.00% compared to DURECT's net margin of -323.16%. Qilian International Holding Group's return on equity of 0.00% beat DURECT's return on equity.
Summary
Qilian International Holding Group beats DURECT on 9 of the 13 factors compared between the two stocks.
Get DURECT News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
